Ashleigh Stewart
The Hertz Corporation
PharmacokineticsCancerAntibodyConjugateAntibody-drug conjugateTolerabilityDrugSolid tumourLoading ratioCurrent technologyAntibody fragmentsPatient benefitComputer scienceCancer researchPotencyComputational biologyMedicine
3Publications
2H-index
28Citations
Publications 2
Newest
#1Mahendra DeonarainH-Index: 19
#2Gokhan YahiogluH-Index: 24
Last. Quinn XueH-Index: 1
view all 12 authors...
Antibody Drug Conjugates (ADCs) are failing due to 3 critical limitations: Low potency, ineffective solid-tumour penetration and poor tolerability. The industry is full of approaches where full-length Immunoglobulins have been engineered to carry defined numbers of payloads with higher-loadings of less potent payloads appearing to be well-tolerated. However, antibody fragments (e.g. single-chain Fcs-scFvs), which have many advantages including rapid tumour penetration, faster clearance, inexpens...
2 CitationsSource
#1M P Deonarain (The Hertz Corporation)H-Index: 3
#2Gokhan Yahioglu (The Hertz Corporation)H-Index: 24
Last. Ashleigh Stewart (The Hertz Corporation)H-Index: 2
view all 8 authors...
Antibody–Drug Conjugates (ADCs) have been through multiple cycles of technological innovation since the concept was first practically demonstrated ~40 years ago. Current technology is focusing on large, whole immunoglobulin formats (of which there are approaching 100 in clinical development), many with site-specifically conjugated payloads numbering 2 or 4. Despite the success of trastuzumab-emtansine in breast cancer, ADCs have generally failed to have an impact in solid tumours, leading many t...
22 CitationsSource